Neurology
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
Oragenics Signs LOI to License CardioDialysis Technology for Brain Disorders
Oragenics Inc. has signed a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology, aiming to combine it with its intranasal neurosteroid candidate ONP-002 for a dual-modality approach to traumatic brain injury and neurodegenerative diseases.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
NeuroOne to Report Fiscal Q2 2026 Financial Results on May 12, Highlights Minimally Invasive Neurological Tech
NeuroOne Medical Technologies will announce its fiscal second quarter 2026 financial results on May 12, 2026, with a focus on its FDA-cleared electrode and ablation systems that aim to reduce hospitalizations and improve outcomes for neurological disorders.
Brain Health Shaped by Lifetime Mental, Physical, Environmental and Lifestyle Factors, New AHA Statement Says
A new American Heart Association scientific statement highlights that brain health is influenced by a range of factors across the entire lifespan, including mental health, sleep, environment, and social conditions, offering opportunities for early intervention to reduce the risk of stroke, cognitive decline, and dementia.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform
NeuroOne Medical Technologies is collaborating with the University of Minnesota to develop a brain drug delivery system that could revolutionize epilepsy treatment by delivering therapies directly to seizure sites, potentially improving efficacy while reducing side effects.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Wireless Brain Implants Could Revolutionize Neurological Treatment Without Surgery
MIT researchers have developed microscopic wireless implants that can navigate to brain tissue autonomously, potentially eliminating the need for surgery in treating tumors and neurological conditions.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
NeuroOne Granted 180-Day Extension to Regain Nasdaq Compliance
NeuroOne Medical Technologies has received an additional 180 days to meet Nasdaq's minimum bid price requirement, providing crucial breathing room for the neurological device company to stabilize its stock performance and avoid potential delisting.
Dr. Hos Loftus Earns 2025 Castle Connolly Top Doctor Recognition for Integrated Neurology and Psychology Care
Dr. Hos Loftus has been recognized as a 2025 Castle Connolly Top Doctor for his innovative integrated approach to neurological and psychological care at Carolinas Institute for Neurology and Psychology, highlighting the growing importance of holistic treatment models in modern healthcare.
Study Reveals Chemotherapy May Damage Brain's Waste Drainage System, Explaining 'Chemo Brain' Symptoms
New research identifies chemotherapy-induced damage to the brain's waste drainage network as a potential cause of cognitive difficulties affecting up to 75% of cancer patients during and after treatment.
Lantern Pharma Partners with Hoth Therapeutics to Deploy AI Platform for Blood-Brain Barrier Prediction
Lantern Pharma's AI platform PredictBBB.ai, which boasts 94% accuracy in predicting drug penetration of the blood-brain barrier, is being deployed through a partnership with Hoth Therapeutics to accelerate neurological drug development.
NeuroOne Expands Executive Leadership with Promotion of Emily Johns to Chief Administrative Officer
NeuroOne Medical Technologies has promoted Emily Johns to Chief Administrative Officer, signaling strategic focus on operational infrastructure as the company scales its neurological disorder treatment technologies.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
NeuroOne Expands Global Patent Portfolio with Key Approvals for Neurological Technology
NeuroOne Medical Technologies has strengthened its intellectual property position with new patent approvals in the US and Europe, signaling expanded opportunities for its neurological disorder treatment technologies.
Glioblastoma Found to Erode Skull Tissue, Challenging Long-Held Treatment Assumptions
A recent study reveals that glioblastoma, the deadliest form of brain cancer, erodes patients' skulls, challenging the long-held assumption that the disease is localized and potentially explaining why current therapies have shown dismal success rates.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
Quantum BioPharma Pioneers Digitally Integrated Biotech Model with Neuroprotective MS Treatment
Quantum BioPharma is transforming biotechnology through a digitally engineered approach that combines clinical innovation with consumer health commercialization and modern market infrastructure.
Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
Oragenics Inc. has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for developing neurological therapeutics, marking a significant expansion beyond its concussion treatment program.
NeuroOne Reports 163% Revenue Growth Driven by Epilepsy Treatment Technology
NeuroOne Medical Technologies announced record preliminary product revenue of $9.1 million for fiscal 2025, representing 163% growth driven by increased adoption of its OneRF Ablation system for epilepsy treatment.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Lantern Pharma's AI Platform Helps Hoth Therapeutics Accelerate Drug Development
Hoth Therapeutics is using Lantern Pharma's PredictBBB.ai platform to streamline drug candidate selection by predicting blood-brain barrier penetration with 94% accuracy, potentially accelerating development of neurological treatments.